➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Moodys
Express Scripts
McKesson
Mallinckrodt

Last Updated: April 14, 2021

DrugPatentWatch Database Preview

ACYCLOVIR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Acyclovir patents expire, and what generic alternatives are available?

Acyclovir is a drug marketed by Actavis Elizabeth, Apotex, Cadila, Cadila Pharms Ltd, Carlsbad Technology, Chartwell Molecules, Dava Pharms Inc, Heritage Pharms Inc, Ivax Sub Teva Pharms, Kenton, Lek Pharm, Mylan, Ranbaxy, Roxane, Teva, Teva Pharms, Watson Labs, Yiling, Amneal, Perrigo Uk Finco, Abbvie, Alembic Pharms Ltd, Amneal Pharms, Anda Repository, Cipla, Cosette, Fougera Pharms Inc, Glenmark Pharms Sa, Mylan Pharms Inc, Solaris Pharma Corp, Taro, Torrent, Xiromed, Actavis Mid Atlantic, Akorn, Novitium Pharma, Apotex Inc, Carlsbad, Hetero Labs Ltd V, Square Pharms Ltd, Sun Pharm Inds Ltd, Zydus Pharms, Eurohlth Intl Sarl, Apothecon, Athenex Inc, Aurobindo Pharma Ltd, Exela Pharma, Fresenius Kabi Usa, Hikma, Hospira, Mylan Labs Ltd, and Teva Parenteral. and is included in seventy-eight NDAs.

The generic ingredient in ACYCLOVIR is acyclovir sodium. There are fifty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the acyclovir sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Acyclovir

A generic version of ACYCLOVIR was approved as acyclovir sodium by FRESENIUS KABI USA on May 13th, 1998.

  Start Trial

Drug patent expirations by year for ACYCLOVIR
Drug Prices for ACYCLOVIR

See drug prices for ACYCLOVIR

Drug Sales Revenue Trends for ACYCLOVIR

See drug sales revenues for ACYCLOVIR

Recent Clinical Trials for ACYCLOVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Alabama at BirminghamPhase 1
Dr. Amr Arafa AlbadryN/A
Tanta UniversityN/A

See all ACYCLOVIR clinical trials

Medical Subject Heading (MeSH) Categories for ACYCLOVIR

US Patents and Regulatory Information for ACYCLOVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva ACYCLOVIR acyclovir TABLET;ORAL 074556-002 Apr 22, 1997 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan Labs Ltd ACYCLOVIR SODIUM acyclovir sodium INJECTABLE;INJECTION 203927-001 Mar 29, 2017 DISCN No No   Start Trial   Start Trial   Start Trial
Heritage Pharms Inc ACYCLOVIR acyclovir SUSPENSION;ORAL 212718-001 Apr 23, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Boehringer Ingelheim
Medtronic
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.